X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8) 8
index medicus (8) 8
oncology (8) 8
cancer (7) 7
female (7) 7
middle aged (7) 7
aged (6) 6
adult (4) 4
aged, 80 and over (4) 4
male (4) 4
prognosis (4) 4
cancer therapies (3) 3
care and treatment (3) 3
clinical trials (3) 3
mutation (3) 3
neoplasm staging (3) 3
survival (3) 3
treatment outcome (3) 3
acetylation (2) 2
breast (2) 2
chemotherapy (2) 2
context (2) 2
disease-free survival (2) 2
endometrial cancer (2) 2
endometrial neoplasms - drug therapy (2) 2
endometrial neoplasms - genetics (2) 2
endometrial neoplasms - pathology (2) 2
erbb-2 protein (2) 2
follow-up studies (2) 2
hematology, oncology and palliative medicine (2) 2
i trials (2) 2
inhibitor (2) 2
lung neoplasms - drug therapy (2) 2
medical prognosis (2) 2
medical research (2) 2
medical treatment (2) 2
metastasis (2) 2
monosaccharides (2) 2
mortality (2) 2
mutant-cells (2) 2
neoplasm metastasis (2) 2
neoplasm recurrence, local - drug therapy (2) 2
neoplasm recurrence, local - genetics (2) 2
neoplasm recurrence, local - pathology (2) 2
neoplasms - drug therapy (2) 2
neoplasms - mortality (2) 2
neoplasms - therapy (2) 2
olaparib (2) 2
ovarian cancer (2) 2
participants (2) 2
patient selection (2) 2
patients (2) 2
peritoneal neoplasms - drug therapy (2) 2
peritoneal neoplasms - genetics (2) 2
poly polymerase (2) 2
prognostic-factors (2) 2
reproducibility of results (2) 2
suberoylanilide hydroxamic acid (2) 2
sugars (2) 2
tumors (2) 2
4-beta-hydroxycholesterol (1) 1
abridged index medicus (1) 1
acute myeloid-leukemia (1) 1
acute promyelocytic leukemia (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - pathology (1) 1
adenomatous polyposis coli (1) 1
administration, oral (1) 1
albumin (1) 1
albumins - analysis (1) 1
analysis (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - pharmacokinetics (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antiparasitic agents (1) 1
area under curve (1) 1
article (1) 1
azabicyclo compounds - pharmacokinetics (1) 1
azabicyclo compounds - therapeutic use (1) 1
benzimidazoles - administration & dosage (1) 1
bibf-1120 (1) 1
biomarkers (1) 1
blood (1) 1
blood platelets - pathology (1) 1
brain (1) 1
brain neoplasms - drug therapy (1) 1
brain neoplasms - genetics (1) 1
brain neoplasms - secondary (1) 1
brain tumors (1) 1
brca1 protein - genetics (1) 1
brca2 protein - genetics (1) 1
breast cancer (1) 1
brief communication (1) 1
brivanib (1) 1
cancer detection and diagnosis (1) 1
cancer genomics (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2016, Volume 38, Issue 10, pp. 2286 - 2299
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 05/2011, Volume 8, Issue 5, pp. 302 - 306
Journal Article
Journal Article
by Earl, Helena and Earl, Helena M and Hiller, Louise and Vallier, Anne-Laure and Loi, Shrushma and McAdam, Karen and Hughes-Davies, Luke and Harnett, Adrian N and Ah-See, Mei-Lin and Simcock, Richard and Rea, Daniel and Raj, Sanjay and Woodings, Pamela and Harries, Mark and Howe, Donna and Raynes, Kerry and Higgins, Helen B and Wilcox, Maggie and Plummer, Chris and Mansi, Janine and Gounaris, Ioannis and Mahler–Araujo, Betania and Provenzano, Elena and Chhabra, Anita and Abraham, Jean E and Caldas, Carlos and Hall, Peter S and McCabe, Christopher and Hulme, Claire and Miles, David and Wardley, Andrew M and Cameron, David A and Dunn, Janet A and Agarwal, Roshan and Algurafi, Hafiz and Allerton, Rozenn and Archer, Caroline and Armstrong, Anne and Bale, Catherine and Barraclough, Lisa and Barthakur, Urmila and Bedi, Carolyn and Benstead, Kim and Bloomfield, David and Bowen, Rebecca and Bradley, Chris and Brown, Jane and Butt, Mohammad and Churn, Mark and Cleator, Susan and Cliff, Joanne and Crellin, Perric and Daly, Margaret and De Silva-Minor, Shiroma and Dhadda, Amandeep and Din, Omar and Down, Sue and Eaton, David and Eichholz, Andrew and Epurescu, Daniel and Goh, Chee and Goodman, Andrew and Grieve, Robert and Hadaki, Maher and Harper-Wynne, Catherine and Hayward, Larry and Humphreys, Alison and Innes, Helen and Jafri, Mariam and Jegannathen, Apurna and Kelleher, Muireann and Kristeleit, Hartmut and Lee, Daniela and Lupton, Susan and MacGregor, Carol and Malik, Zafar and Marshall, Jennifer and McGolick, Trevor and Mehra, Rakesh and Mithal, Natasha and Moss, Charlotte and Moss, Aian and Mukesh, Mukesh and Neal, Anthony and Nelmes, Daniel and Neville-Webbe, Helen and Newby, Jacqueline and O'Reilly, Susan and Ostler, Peter and Persic, Mojca and Pettit, Laura and Raja, Fharat and Reed, Catherine and Rigg, Anne and Roe, Helen and Shah, Nihal and Simmonds, Peter and Sims, Eliot and Smith, Sarah and Storey, Nicola and ... and PERSEPHONE Steering Comm & Trial and PERSEPHONE Steering Committee and Trial Investigators
The Lancet, ISSN 0140-6736, 06/2019, Volume 393, Issue 10191, pp. 2599 - 2612
Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | HERCEPTIN | RECOMMENDATIONS | CARDIAC EVENTS | FOLLOW-UP | OPEN-LABEL | CHEMOTHERAPY | NEOADJUVANT PERTUZUMAB | PLUS | Breast cancer | Medical research | Toxicity | Research & development--R&D | Medical treatment | Cancer therapies | Survival | ErbB-2 protein | Chemotherapy | Hypotheses | Randomization | Motivation | Technology assessment | Breast | Trastuzumab
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/2018, Volume 119, Issue 4, pp. 487 - 491
Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are... 
ONCOLOGY | METASTASIS | Brain | Invasiveness | Brain tumors | Glioblastoma | Patients | ErbB-2 protein | Gene sequencing | Necrosis | Adenomatous polyposis coli | Janus kinase 2 | Clusters | Pleomorphism | Tumors | Cancer | Brief Communication | CNS cancer | Cancer genomics
Journal Article